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ABSTRACT:
 Hepatocellular carcinoma (HCC) is the most common liver cancer, accounting 
for 90% of primary liver cancers. In the last decade it has become one of the most 
frequently occurring tumors worldwide and is also considered to be the most lethal 
of the cancer systems, accounting for approximately one third of all malignancies.
 Although the clinical diagnosis and management of early-stage HCC has 
improved significantly, HCC prognosis is still extremely poor. Furthermore, advanced 
HCC is a highly aggressive tumor with a poor or no response to common therapies. 
Therefore, new effective and well-tolerated therapy strategies are urgently needed. 
 Targeted therapies have entered the field of anti-neoplastic treatment and 
are being used on their own or in combination with conventional chemotherapy 
drugs. Molecular-targeted therapy holds great promise in the treatment of HCC. A 
new therapeutic opportunity for advanced HCC is the use of sorafenib (Nexavar). 
On the basis of the recent large randomized phase III study, the Sorafenib HCC 
Assessment Randomized Protocol (SHARP), sorafenib has been approved by the FDA 
for the treatment of advanced HCC. Sorafenib showed to be able to significantly 
increase survival in patients with advanced HCC, establishing a new standard of care. 
Despite this promising breakthrough, patients with HCC still have a dismal prognosis, 
as it is currently the major cause of death in cirrhotic patients. Nevertheless, the 
successful results of the SHARP trial underscore the need for a comprehensive 
understanding of the molecular pathogenesis of this devastating disease.
 In this review we summarize the most important studies on the 
signaling pathways implicated in the pathogenesis of HCC, as well as 
the newest emerging drugs and their potential use in HCC management.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
common liver cancer, accounting for 90% of primary 
liver cancers. In the last decade it has become one of the 
most frequently occurring tumors worldwide and is also 
considered to be the most lethal of the cancer systems, 
accounting for approximately one third of all malignancies 
[1, 2]. Distribution, however, is not homogeneous around 
the world, as important differences have been noted 
between countries, with most cases occurring in Eastern 
Asia and sub-Saharan Africa, while low rate areas are 
in North America, northern Europe and Australia [3, 
4]. Changes in liver cancer incidence are beginning 
to be reported, namely a certain degree of reduction in 
the high-rate areas, particularly in China, thanks to the 
implementation of universal hepatitis B virus vaccination 
and limitation to aflatoxin B1 exposure [5, 6], while 
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increasing incidences are being reported in low-rate areas, 
particularly in the United Kingdom and Australia [7].
By far the most frequent risk factor for HCC is liver 
cirrhosis (LC), this underlying disease being present 
in a variable proportion of cases, reaching a 90% rate 
in western countries [8]. The main etiological agents of 
LC are the hepatitis B (HBV) and hepatitis C (HCV) 
viruses, which together account for three quarters of all 
HCC cases worldwide. The diffusion of these viruses in 
the world reflects regional differences in the quantitative 
and qualitative (etiological) pattern of HCC. Other risk 
factors include aflatoxin B1 intake, alcohol consumption, 
non-alcoholic fatty liver disease (NAFLD) and some 
hereditary diseases, including hereditary hemochromatosis 
[9]. In the last few years a great body of evidence has been 
reported about the possibility that some severe forms of 
NAFLD may progress to HCC. NAFLD is usually part of 
the metabolic syndrome, found namely in patients with 
diabetes mellitus, hypertension, dyslipidemia, obesity and 
insulin resistance, which is becoming very frequent in 
western populations, due to their life style (sedentariness) 
and diet. It has also been called into question in many 
cases of HCC of “cryptogenetic” origin [10-12]. In 
particular, several studies suggest that obese patients are 
also at increased risk for several types of cancer, including 
HCC. Recently, a meta-analysis found that the relative 
risks (RR) for liver cancer were higher in obese (Body 
Mass Index, BMI 30) than in overweight subjects (BMI 
= 25–30) [13].
HCC predominantly affects males, with a male to 
female ratio averaging 2:1 and 4:1 [9], although after the 
menopause no significant differences have been reported 
between the sexes [14]. For this reason sex hormones 
have been thought to play a possible role in neoplastic 
degeneration and various therapeutic evaluations based 
on anti-androgen or anti-estrogen agents have been 
performed, albeit with disappointing results [15].
We can therefore state that the pathogenesis of 
HCC is very complex and not completely clear. As in 
most cancers, HCC pathogenesis is a multistep process, 
involving sequential events such as chronic inflammation, 
hyperplasia and dysplasia and ultimately malignant 
transformation. It is a very long process, which usually 
takes even up to 30 years and during these years there are 
a number of epigenetic and genetic alterations, ultimately 
leading to an alteration in the molecular pathways. 
Several results indicate that there is no dominant pathway 
specifically altered in HCC [16]. Indeed, there are several 
subclasses of tumors presenting distinct molecular 
aberrations responsible for cell proliferation and survival, 
while other alterations present in almost all tumors 
involve limitless replicative potential, neoangiogenesis, 
and insensitivity to antigrowth signals and checkpoint 
disruption [16]. Recent discoveries in the complex 
networks involved in HCC proliferation, progression and 
survival have created many opportunities for targeted 
drugs and new therapeutic approaches to this disease. 
These new targets include signal transduction pathways, 
oncogenes and growth factors and their receptors. 
In this review we will focus on the most frequently 
dysregulated signaling pathways implicated in the 
pathogenesis of HCC, as well as the newest emerging 
drugs and their potential use in the management of HCC.
SIGNALING PATHWAYS 
The key signal transduction pathways that have 
been implicated in the pathogenesis of HCC include 
those mediated by epidermal growth factor (EGF)/EGF 
receptor (EGFR), vascular endothelial growth factor 
(VEGF)/VEGF receptor (VEGFR), platelet-derived 
growth factor (PDGF)/PDGF receptor (PDGFR), insulin-
like growth factor (IGF)/IGF receptor (IGFR), and the 
Ras/Raf/mitogen-extracellular activated protein kinase 
kinase (MEK)/ extracellular signal-regulated kinase 
(ERK), Wnt/β-catenin, and phosphatidylinositol-3-
kinase (PI3K)/phosphatase and tensin homologue deleted 
on chromosome ten (PTEN)/Akt/mammalian target of 
rapamycin (mTOR) signaling pathways (Figures 1-3). 
Further attention is required to determine the relevance 
and therapeutic potential of other pathways involved in 
liver carcinogenesis, such as the interleukin 6 (IL-6), 
signal transducer and activator of transcription (STAT) and 
Hedgehog signaling pathways.
Activation of these pathways will eventually lead to 
resistance to apoptosis, cell proliferation, the stimulation 
of angiogenesis, invasiveness and metastasis. In the 
past decade there has been significant breakthroughs in 
the discovery of interacting pathway components and 
insights into how mutations of these components can 
lead to aberrant signaling, uncontrolled proliferation and 
even sensitivity/resistance to targeted therapy [17-19]. 
Research has resulted in to the development of inhibitors 
that specifically target critical elements of these pathways 
as well as the concept that mutations at one signaling 
molecule in the pathways (e.g., EGFR, Ras, B-Raf) may 
prevent sensitivity to an inhibitor targeting a downstream 
component (e.g., Raf, MEK or PI3K) [20-25]. These 
studies indicate that the mutational status of key genes in 
the pathway (e.g., Ras, B-Raf) will have to be determined 
in cancer patients before applications of targeted therapy 
[17]. While sensitivity to EGFR inhibitors in non small 
cell lung carcinomas (NSCLC) is often due to mutations 
(L858R) or small deletions in exon 19 in the kinase 
domain, initial sensitivity to EGFR inhibitors may be 
lost due to subsequent mutations in the kinase domain. 
Other mutations in the kinase domain of EGFR prevent 
the induction of pro-apoptotic Bim in response to EGFR 
inhibitors. In some cases of NSCLC which have become 
resistant to EGFR inhibitors, they over express the c-Met 
proto-oncogene. Finally K-Ras mutations confer resistance 
to EGFR inhibitors (erlotinib, gefitinib or antibodies such 
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as cetuximab). In some cases resistance to either Raf/
MEK or PI3K may occur as some upstream mutations 
(e.g., EGFR mutations) activate both Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR signaling pathways. Treatment 
of cells with Ras mutations with certain mutant allele 
selective B-Raf inhibitors can result in Raf-1 activation. 
Dominant negative B-Raf mutations can still bind and 
activate Raf-1 if the cell has a mutant Ras allele. Finally 
some B-Raf inhibitor resistant cells overexpress various 
critical cell cycle regulatory molecules such as cyclin D. 
The various mechanisms of inhibitor resistance involving 
other components in these pathways are explained in more 
detail in McCubrey et al. [17]. Many recent studies are 
directed at increasing cancer patient survival by targeting 
these and other pathways in cancer cells.
Illustrations of the most important receptors and 
intracellular molecular signaling pathways, as well as 
sites of intervention with small molecule inhibitors 
and monoclonal antibodies are presented in Figures 
1-2. Certain molecular-targeted agents are actually 
promiscuous (e.g. sorafenib, regorafenib, sunitinib, 
brivanib and others), i.e. they simultaneously target 
more than one molecule and this multiple targeting could 
enhance their therapeutic efficacy, while others act on a 
single target (e.g. AZD6244, AZD8055, everolimus and 
others) (Figure 1).
EGF/EGFR PATHWAY
The EGFR (also known as ErbB1 and Her1) belongs 
to the ERB family of receptor tyrosine kinases (RTKs), 
which includes ErbB2 (also known as Her2), ErbB3 
(also known as Her3) and ErbB4 (also known as Her4). 
The members are all endowed with tyrosine kinase (TK) 
activity, with the exception of ErbB3. All members 
share a common structure, showing an extracellular 
ligand-binding domain, a transmembrane domain and an 
intracellular domain where the tyrosine kinase activity 
resides. EGFR forms homo- or heterodimers upon ligand 
binding. Dimerization results in auto-phosphorylation 
of EGFR with the subsequent activation of a number of 
downstream signaling pathways, including the PI3K/Akt/
mTOR and the Ras/Raf/MEK/ERK pathways (Figure 2). 
With the exception of ErbB2, which has no ligand, all 
the other members can bind a family of growth factors. 
Ligands for EGFR are EGF, TGF-α, epigenin (EPG), 
amphiregulin (AREG), heparin-binding-EGF (HB-EGF), 
epirugulin (EREG) and β-cellulin (BTC) and the last 
three ligands are also able to bind to ErbB4/Her4. The 
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Figure 1: Relevant receptors and corresponding molecular targeted agents currently tested in preclinical and clinical 
HCC trials.
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neuregulin (NRG) ligands NRG-1 and NGR-2 bind to both 
ErbB3/Her3 and ErbB4/Her4, whereas NGR-3 and NGR-4 
only recognize ErbB4/Her4.
The receptor most studied in HCC is EGFR/
ErbB1. The rationale for targeting the EGFR pathway 
comes from the following observations: there is a high 
frequency of EGFR overexpression in HCC [26-29], 
and this overexpression has been associated with late-
stage disease, increased cell proliferation and degree of 
tumor differentiation [28-30]. In addition, activation of 
the EGFR pathway is a prognostic predictor of survival 
in patients with HCC [31]. Therefore, EGFR represents a 
good potential molecular target for the biological therapy 
of HCC.
The importance of EGF/EGFR signaling in the 
development of HCC has been confirmed in two recent 
studies showing that cirrhotic patients with high levels 
of serum and tissue EGF have a higher adjusted risk of 
developing HCC compared to cirrhotic patients with 
EGF levels comparable to healthy subjects [32, 33]. 
High levels of EGF are due to the presence of a single-
nucleotide polymorphism in the EGF gene, involving A to 
G transition at position 61 in the 5′ untranslated region of 
the EGF gene (SNP rs4444903). The transcript of patients 
with SNP exhibited more than a 2-fold longer half-life 
than those from the wt allele and serum EGF levels were 
1.8-fold higher in G/G patients than A/A patients, while 
liver EGF levels were 2.4-fold higher in G/G patients than 
in A/A patients. Whether higher EGF levels are associated 
with a greater risk of developing cirrhosis and a shorter 
time taken to develop cirrhosis were aspects not addressed 
by this study. However, the observation that the severity 
of cirrhosis did not differ between A/A, A/G, and G/G 
patients argues against this possibility [32].
RAS/RAF/MEK/ERK PATHWAY
The Ras/Raf/MEK/ERK pathway, also known as the 
MAPK (mitogen-activated protein kinase) pathway, is a 
signaling pathway consisting of a kinase cascade regulated 
by phosphorylation and de-phosphorylation by specific 
kinases and phosphatases as well as GTP/GDP exchange 
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Figure 2: Schematic overview of PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways stimulated 
after binding of a growth factor (GF) to a receptor tyrosine kinase.
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Agent as monotherapy Target Design
Clinicaltrials
.gov 
Identifier
Sorafenib (Nexavar, BAY43-9006; Bayer) BRAF, VEGFR-2, VEGFR-3, PDGFR-
b, c-KIT, Flt3
Registered
Regofarenib (fluoro-sorafenib, BAY73-4506; Bayer) BRAF, VEGFR-2, VEGFR-3, PDGFR-
b, c-KIT, Flt3, Tie2
Phase I/II NCT01117623; 
NCT01003015
Sunitinib (Sutent, SU11248; Pfizer) VEGFR-1 VEGFR-2, PDGFR-α, 
PDGFR-b, c-KIT, Flt3, RET, CSF-1R
Phase III NCT00699374
Brivanib (BMS-582664; Bristol-Meyers Squibb) VEGFR- 2, VEGFR-3, FGFR-2, FGFR-
3
Phase III NCT00858871; 
NCT00825955
Linifanib (ABT-869; Abbott) VEGFR-2, PDGFR-b, CSF-1R Phase II NCT00517920; 
NCT01009593
Pazopanib (GW786034, Votrient; GalxoSmithKline) VEGFR-1, VEGFR-2, VEGFR-3, 
PDGFR-α, PDGFR-b, c-KIT
Phase I NCT00370513
TSU-68 (SU6668; Taiho) VEGFR-2, PDGFR-β, FGFR-1 Phase I/II NCT00784290
Foretinib (XL880, GSK1363089; GlaxoSmithKline) VEGFR-2; c-MET Phase I/II NCT00920192
E7080 (Eisai) VEGFR-1, VEGFR-2, VEGFR-3 Phase I/II NCT00946153
BIBF 1120 (Vargatef; Boeringer Ingelheim) VEGFR-2, PDGFR-b, FGFR Phase II NCT00987935
XL184 (BMS907351; Bristol-Meyers Squibb) VEGFR-2; c-MET Phase II NCT00940225
Dovitinib (TKI258; Novartis) VEGFR-1, VEGFR-2, VEGFR-3, 
PDGFR-b, FGFR-3, Flt3, c-KIT, CSF-
1R
Phase II NCT01232296
Cediranib (Recentin, AZD2171; AstraZeneca) VEGFR-2 Phase II NCT00427973; 
NCT00238394
Vandetanib (Zactima, ZD6474; AstraZeneca) VEGFR, RET, EGFR Phase I/II NCT00496509; 
NCT00508001
Foretinib (XL880, GSK1363089; GlaxoSmithKline) VEGFR-2, c-Met Phase I NCT00920192
Ramucirumab (IMC-1121B; ImClone Systems Inc) VEGFR-2 Phase II/III NCT00627042; 
NCT01140347 
Bevacizumab (Avastin; Genetech/Roche) VEGF Phase II NCT00162669
Erlotinib (Tarceva, OSI774; Genetech) EGFR Phase I/II NCT00047346; 
NCT00047333
Lapatinib (Tyverb, GW572016; GlaxoSmithKline) EGFR, HER2/neu Phase II NCT00107536; 
NCT00101036
Gefitinb (Iressa, ZD1839; AtraZeneca) EGFR Pahse II NCT00071994; 
NCT00282100
Cetuximab (Erbitux, IMC-C225;  Bristol-Meyers Squibb, Merck 
Serono)
EGFR Phase II NCT00142428
OSI-906 (OSI Pharmaceuticals ) IGF-1R, IR Phase II NCT01101906
Cixutumumab (IMC-A12; ImClone Systems Inc) IGF-1R Phase II NCT00639509
BIIB022 (Biogen-Idec) IGF-1R Phase I NCT00555724
AVE1642 (Sanofi-Aventis) IGF-1R Phase I/II NCT00791544
Everolimus (RAD001; Novartis) mTOR Phase I/II NCT00390195
Temsirolimus (Torisel; Wyeth Pharmaceuticals, Inc) mTOR Pahse II NCT01079767; 
NCT01251458
AZD8055 (AstraZeneca) mTOR Phase I/II NCT00999882
ARQ197 (ArQule, Inc) c-Met Phase I/II NCT00802555; 
NCT00988741
MK-2206 (Merck & Co., Inc.) Akt Phase II NCT01239355
AZD6244 (ARRY-142886, Selumetinib; AstraZeneca) MEK Phase I/II NCT00550719; 
NCT00604721
Table I: Trials of molecular targeted agents in HCC
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proteins, adaptor proteins and scaffolding proteins (Figure 
2). In response to a variety of cellular stimuli, including 
growth factor-mediated activation of receptor tyrosine 
kinases (RTKs), Ras assumes an activated GTP-bound 
state, leading to recruitment of Raf from the cytosol to 
the cell membrane, where it becomes activated, likely via 
a Src-family tyrosine kinase [20, 21, 34-36]. Activated 
Raf causes the phosphorylation and activation of MAP 
kinase extracellular signal-regulated kinases 1 and 2 
(MEK1/MEK2), which in turn phosphorylate and activate 
extracellular signal-regulated kinases 1 and 2 (ERK1/
ERK2) at specific Thr and Tyr residues [37]. Activated 
ERK can translocate into the nucleus and phosphorylate 
additional transcription factors, such as Elk-1, CREB, 
Fos and globin transcription factor 1 (Gata-1) as well as 
others, which bind promoters of many genes, including 
growth factor and cytokine genes, which are important 
in promoting growth and preventing the apoptosis of 
multiple cell types [38-40].
Deregulation of the Ras/Raf/MEK/ERK pathway 
plays a key role in the pathogenesis of several human 
cancers [17, 41, 42], including HCC [21, 43-48]. 
Although mutations of Ras and Raf occur infrequently in 
HCC, a recent study demonstrated that activation of the 
Ras pathway was observed in 100% of HCC specimens 
analyzed when compared with non-neoplastic surrounding 
tissue and normal livers. This increased expression of 
Ras coincided with the decreased expression of genes 
which serve to inhibit Ras expression, namely the Ras-
association domain family 1A (RASSF1A) and the 
novel Ras effector 1A (NORE1A). These genes may be 
suppressed due to aberrant methylation of their promoters 
[49]. In addition, activation of the Ras/Raf/MEK/ERK 
pathway in HCC may be due to the down-regulation of 
Ras inhibitors Sprouty and Sprouty-related protein with 
Ena/vasodilator-stimulated phosphoprotein homology-1 
domain (Spred-1) and Spred-2 [50, 51]. It has been 
shown that the expression of Spred-1 and -2 in human 
HCC tissues is frequently lower than in the adjacent non-
tumor tissue and inversely correlates with the incidence 
of tumor invasion and metastasis [51]. Moreover, forced 
expression of Spred inhibited HCC cell proliferation both 
in vitro and in vivo, which was associated with reduced 
ERK activation, suggesting that Spred could be not only 
a novel prognostic factor but also a new therapeutic target 
for human HCC [51]. Recently, studies have also shown 
that down-regulation of Raf kinase inhibitor protein 
(RKIP) expression is a major factor in the activation of the 
ERK/MAPK pathway during human liver carcinogenesis 
[52, 53].
Deregulation of the ERK pathway has clinical 
importance in HCC. Activation of the ERK signaling 
pathway predicts poor prognosis in hepatocellular 
carcinoma [54]. The important role of ERK signaling 
has also been suggested for HCC progression in obese 
patients. A possible explanation for an associated risk for 
obesity and HCC comes from the study of Saxena et al., 
which for the first time demonstrated that leptin, a key 
molecule involved in the regulation of energy balance 
and body weight control, promotes HCC growth and 
invasiveness through activation of ERK signaling [55].
Other well known risk factors for HCC such as HBV 
and HCV infection also seem to utilize the Raf/MEK/ERK 
pathway for the control of hepatocyte survival and viral 
replication [56, 57]. HBx, one of the four proteins encoded 
by the HBV genome, has been reported to be involved 
in liver carcinogenesis, with HBx expression activating 
the Ras, Raf, MAP kinase signaling cascade [56, 58-60]. 
Among the HCV components, the core protein has been 
reported to activate the Ras/Raf/MEK/ERK pathway and 
thereby might contribute to HCC carcinogenesis [57, 61, 
62]. Therefore, these studies suggested the possible use 
of the Raf/MEK/ERK pathway as a target in therapeutic 
Table I Continued
Combination of 
targeted agents Design
Clinicaltrials
.gov 
Identifier
Sorafenib + Erlotinib Phase III NCT00901901 
Sorafenib + AVE1642 Phase I/II NCT00791544
Sorafenib + BIBF 1120 NCT01004003
Sorafenib + Panobinostat
(LBH589, Novartis)
Phase I NCT00823290
Sorafenib + Cixutumumab Phase I NCT01008566; 
NCT00906373
Sorafenib + OSI-906 Phase III NCT01334710
Sorafenib + BIIB022 Phase I NCT00956436
Sorafenib + Temsirolimus Phase I/II NCT01008917; 
NCT01335074
Sorafenib + ARQ197 Phase I NCT00827177
Sorafenib + AZD6244 Phase I/II NCT01029418
Erlotinib + Bevacizumab Phase II NCT01180959; 
NCT00242502; 
NCT00287222; 
NCT00365391 
Erlotinib + AVE1642 Phase I/II NCT00791544
Erlotinib + Celecoxib Phase I/II NCT00293436 
Bevacizumab + Everolimus Phase II NCT00775073
Targeted agents in 
combination with 
cytotoxic therapy
Design
Clinicaltrials
.gov 
Identifier
Erlotinib + Gemcitabine-
Oxaliplatin (GEMOX)
Phase II NCT00832637
Erlotinib + Docetaxel Phase II NCT00047333; 
NCT00532441
Cetuximab + Capecitabine-
Oxaliplatin (CAPEOX)
Phase II NCT00483405
Bevacizumab + transarterial 
chemoembolisation (TACE)
Phase II NCT00280007
Bevacizumab + Gemcitabine-
Oxaliplatin (GEMOX)
Phase II NCT00142467
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approaches for the treatment of HCC resulting from HBV 
and HCV infection. Taken together, these data suggest that 
the Raf/MEK/ERK pathway may represent an important 
therapeutic target for the treatment of HCC in patients 
with differing etiologies that lead to the development of 
this aggressive tumor.
Activation of Ras/Raf/MEK/ERK signaling in HCC 
may result from up-regulation of IGF [63], aberrant 
upstream EGFR signaling [64] and other receptor signaling 
(i.e. VEGFR and PDGFR). An effective blockade of the 
Ras/Raf/MEK/ERK pathway can be achieved using small 
molecules, such as lonafarnib, sorafenib, regorafenib, 
AZD6244 and others (Figures 1 and 2). Drugs inhibiting 
components of the Ras/Raf/MEK/ERK pathway, with the 
exception of sorafenib, are still in the pre-clinical phase 
or in phase I/II clinical trials for HCC therapy (Table 1).
PI3K/PTEN/AKT/MTOR PATHWAY
The PI3K/PTEN/Akt/mTOR pathway is another key 
pathway in HCC, its activation inducing cell proliferation 
and increasing survival. This pathway is activated after 
the binding of different growth factors to specific cell 
surface receptors, such as EGFR and IGF-1R (Figure 2). 
PI3K is a heterodimeric protein with an 85-kDa regulatory 
subunit and a 110-kDa catalytic subunit (PIK3CA). 
PI3K serves to phosphorylate a series of membrane 
phospholipids including PtdIns(4)P and PtdIns(4,5)P2, 
thereby forming the second messenger lipids PtdIns(3,4)
P2 (PIP2) and PtdIns(3,4,5)P3 (PIP3). PIP3 then activates 
the phosphotidylinositide-dependent kinases (PDKs) 
which are responsible for activation of serine-threonine 
kinase Akt/protein kinase B (PKB) (Figure 2). Once 
activated, Akt leaves the cell membrane to phosphorylate 
intracellular substrates, including caspase-9 [65], the 
pro-apoptotic molecule BAD [66, 67], GSK-3β [68], 
and kinase IκB (IKK) [69]. When these targets are 
phosphorylated by Akt, they may either be activated or 
inactivated (e.g. phosphorylated BAD is inactive), but 
the final result is to promote cell survival. As well as 
intracellular substrates, Akt is able to target a number of 
transcription factors. In fact, after activation Akt is able 
to translocate into the nucleus [70] where it affects the 
activity of a number of transcriptional regulators, such as 
cAMP response element-binding (CREB) [71], E2F [72, 
73], NF-κB (via IKK) [69], and the forkhead transcription 
factors [74-77].
Activated Akt positively modulates mTOR function. 
mTOR phosphorylates components of the protein 
synthesis machinery, such as the serine-threonine kinase 
p70S6 (40S ribosomal protein kinase) and the translation 
repressor eukaryotic initiation factor 4E-binding protein-1 
(4E-BP1), both regulating the translation of important 
factors involved in cell proliferation (such as c-myc, cyclic 
D1 and pRb) and angiogenesis (such as HIF1-α).
Negative regulation of the PI3K pathway is primarily 
accomplished through the action of the PTEN tumor 
suppressor protein. PTEN in turn dephosphorylates PIP3, 
thus inhibiting the PI3K/Akt pathway.
Activation of PI3K/PTEN/Akt/mTOR signaling 
through the mutation, inactivation or silencing of pathway 
components occurs in various malignancies, including 
HCC [78]. Deregulation of this pathway has been 
documented to have clinical importance in HCC. For 
example, recent data from a genomic sequence of HCC 
samples identified mutations in PIK3CA, an upstream 
regulator of Akt, in 50% of patients with poor prognosis 
and survival length < 3 years following partial liver 
resection, whereas only 10% of the HCC patients with a 
good prognosis had a mutation in PIK3CA [79]. Activation 
of Akt is a risk factor for early disease recurrence and 
poor prognosis in patients with HCC [54, 80]. Several 
mechanisms may be responsible for the activation of 
Akt. The high frequency of PIK3CA mutations and/or 
its upregulation in patients with a shorter survival might 
be responsible for the Akt hyperactivation found in HCC 
with poor prognosis [80]. Selective epigenetic silencing 
of multiple inhibitors of the Ras pathway also seems to be 
responsible for the activation of Akt found in HCC [78]. 
Moreover, impaired expression of PTEN is involved in 
the regulation of Akt activity. Activation of Akt signaling 
and a reduced expression of PTEN has been reported in 
40–60% of human HCC [80]. 
The best evidence strongly supporting the connection 
between PTEN suppression and liver carcinogenesis 
comes from genetic studies. All mice with PTEN-deficient 
hepatocytes exhibited liver adenomas and 66% of them 
developed HCC [81]. In these mice, hepatocytes were 
hyperproliferative and displayed an abnormal activation 
of Akt [81]. Furthermore, although mutations in the PTEN 
gene rarely occur in HCC, frequent loss of heterozygosity 
of the PTEN allele has been identified in 20–30% of 
HCC patients [82-85]. In addition, downregulation of 
PTEN expression may be partly due to PTEN promoter 
methylation [86]. Recent studies have also demonstrated 
that PTEN expression plays a critical role in HCC 
progression and patient survival. Patients with a high 
PTEN expression had a significantly better overall survival 
than patients with a low expression [87, 88]. 
An important role of the PI3K/PTEN/Akt/mTOR 
pathway has been suggested for HCC progression in 
obese patients. In the study by Saxena et al., leptin not 
only promoted HCC growth and invasiveness through 
activation of ERK pathway, but also through activation 
of PI3K/PTEN/Akt/mTOR signaling [55]. The other well-
known risk factors, HBV and HCV, also seem to utilize 
the PI3K/PTEN/Akt/mTOR pathway to control hepatocyte 
survival and viral replication [89, 90]. It has been reported 
that HBx expression downregulated PTEN expression in 
hepatocytes [91]. In contrast, PTEN expression in liver 
cells downregulated HBx-induced PI3K and Akt activities 
[92]. Therefore, these studies suggest the possible use of 
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PTEN as a target in therapeutic approaches, at least for the 
treatment of HCC caused by HBV infection.
Recent studies have demonstrated that mTOR 
inhibition shows a remarkable activity against a wide 
range of human cancers in vitro and human tumor 
xenograft models. The mTOR pathway is known to be 
upregulated in a subset of HCC patients [93]. In this 
study 15% of HCC displayed overexpression of phospho-
mTOR, whereas 45% of HCC had increased expression 
of p70 S6K, which correlated with tumor nuclear grade. 
The importance of the mTOR pathway in HCC was 
confirmed by Llovet’s group in a comprehensive study 
with 314 HCC and 37 non-tumor tissues using a series 
of molecular techniques to assess mutation, DNA copy 
number changes, messenger RNA and gene expression, 
as well as protein activation [94]. Aberrant activation of 
mTOR signaling (p-RPS6) was present in half of the cases 
and was associated with IGF pathway activation, EGF 
up-regulation, PTEN dysregulation and chromosomal 
gains in the rapamycin-insensitive companion of mTOR 
(RICTOR) (25% of patients). Furthermore, positive 
p-RPS6 staining correlated with HCC recurrence after 
resection [94]. Overall, these data support efforts to target 
mTOR signaling in liver cancer patients.
Taken together, these data suggest that the PI3K/
PTEN/Akt/mTOR pathway may represent an important 
therapeutic target for HCC treatment in patients with 
differing etiologies that lead to the development of this 
aggressive tumor. 
IGFR PATHWAY
The IGF-I receptor (IGFR) signaling system consists 
of circulating ligands – IGF-I and IGF-II – interacting 
with a membrane receptor, such as type I IGF receptor 
(IGF-1R). The IGF-1R is a heterotetramer consisting of 
two extracellular ligand-binding α subunits and two β 
subunits with transmembrane and TK domains (Figure 1). 
Upon ligand binding IGF-1R undergoes conformational 
changes and phosphorylation, leading to the recruitment 
of insulin-receptor substrates (IRS) and/or Src homology 2 
domain-containing (Shc) proteins, with the consequential 
activation of pathways also common to EGFR, including 
the PI3K/Akt/mTOR-axis and the Ras/MEK/ERK-
pathway (Figure 2).
Constitutive activation of the IGF-signaling axis is 
frequently observed in a wide variety of tumors, including 
HCC [95, 96]. The overexpression of IGF-II, IGF-1R, 
and IRS contributes to cell proliferation and the inhibition 
of apoptosis, as well as increasing invasive behavior in 
HCC [97]. In HCC the reactivation of IGF-signaling 
predominantly occurs at the level of IGF-II expression 
[98, 99], but not of IGF-I. Overexpression of IGF-II has 
been observed in 16-40% of human HCC and around 
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30% of HCC cases overexpress IGF-1R [99, 100]. IGF-II 
overexpression is mainly due to altered methylation of the 
IGF-2 gene promoters P1-P4 [101]. Furthermore, in HBV- 
and HCV-associated HCC, the HBV-derived HBx protein 
and HCV-derived core gene product have been reported 
to facilitate IGF-II overexpression [102, 103]. Moreover, 
in animal models of HCC the IGF signaling system also 
seems to be responsible for the development of HCC 
in obese and diabetic mice. Since obesity and diabetes 
are clearly associated with an increased risk of cancer 
in humans [104, 105], these observations highlighted 
the pivotal role of IGF signaling system in these patient 
categories. 
WNT/Β-CATENIN PATHWAY
The Wnt gene family encodes secreted glycoproteins 
involved in cell growth, differentiation, organogenesis, 
and oncogenesis. In a normal steady state (in the absence 
of Wnt proteins) β-catenin, the central player in the 
canonical Wnt pathway, is phosphorylated at amino-
terminal serine and threonine residues by casein kinase 
1 (CK1) and glycogen synthase kinase 3β (GSK-3β). 
β-catenin phosphorylation is facilitated by the scaffolding 
proteins axin and adenomatous polyposis coli (APC). 
Phosphorylated β-catenin is targeted for ubiquitination 
and protein degradation by the proteasome (Figure 3). 
Wnt signaling events are initiated by the binding of Wnt 
proteins to the seven-pass transmembrane Frizzled (FZD) 
receptor and the coreceptor low-density lipoprotein–
related protein (LRP) 5/6. Then, Dishevelled (Dvl) is 
recruited to the FZD receptor, and the FZD/Dvl complex 
subsequently relocates axin to LRP5/6. The recruitment of 
axin to LRP5/6 is mediated by phosphorylation of LRP5/6 
on key residues by the kinases CK1 and GSK-3β, which 
ultimately leads to GSK-3β inactivation. The absence of 
β-catenin phosphorylation releases it from the degradation 
complex composed of APC, axin, GSK-3β and CK1, 
resulting in an accumulation of β-catenin in the cytoplasm, 
since it cannot be degraded by the ubiquitin-proteasome 
pathway. As a consequence, β-catenin translocates into 
the nucleus where it binds to the lymphoid enhancer 
factor (LEF) or T-cell factor (TCF) transcriptional 
factors, displacing the transcriptional inhibitor Groucho, 
and in complex with LEF/TCF activates the expression 
of different genes which regulate cell proliferation and 
apoptosis (Figure 3).
A role for Wnt/β-catenin signaling in HCC was 
discovered over a decade ago [106]. Activating mutations 
in the β-catenin gene (CTNNB1) were found in different 
human HCC cell lines and in HCC clinical samples in 
around 20%-40% of all cases [106-112]. These mutations 
impair the GSK-3β-mediated phosphorylation of the 
protein at serine and threonine residues in its N-terminus 
region. Intriguingly, HCC occurring in HCV patients 
showed a high incidence of β-catenin gene mutations (up 
to 40% of cases) [109, 113], whereas in HCC occurring 
in HBV patients β-catenin activation is induced in a 
mutation-independent manner by the expression of HBx 
protein [114, 115]. However, in the absence of β-catenin 
gene mutations, aberrant activation of β-catenin has been 
identified in a significant subset of HCC patients with 
mutations in axin1/2 (5%) [116]. The observation that 
expression of the wild-type AXIN1 gene by adenovirus 
mediated gene transfer induced apoptosis in HCC cells, 
which had accumulated β-catenin as a consequence of 
either APC, CTNNB1 or AXIN1 gene mutation, highlights 
the fact that axin may be an effective therapeutic molecule 
for suppressing HCC growth [116]. Recently, since axin 
is the concentration-limiting component of the β-catenin 
destruction complex, stabilization of axin by inhibiting 
the poly-ADP-ribosylating enzymes tankyrase 1 and 
tankyrase 2 with small molecule inhibitor XAV939 has 
been presented as a new avenue for targeted Wnt/β-catenin 
pathway therapies [117].
Moreover, accumulation of β-catenin in human 
HCC tumors containing the wild-type β-catenin gene 
has been observed in the context of up-regulation of the 
FZD7 receptor, which has been found up-regulated in 
90% of human HCC [118-120], suggesting that FZD7 
gene expression is the most common abnormality 
observed in HCC and consequently activation of Wnt/
Frizzled-mediated signaling plays a key role in liver 
carcinogenesis. Accordingly, Nambotin et al. demonstrated 
that pharmacological inhibition of FZD7 displayed anti-
cancerous properties against HCC in vitro (on a panel of 
human HCC cell lines) and in vivo (on the SV40–TAg 
transgenic mouse model of HCC) [121]. Therefore, 
these observations suggest that the Wnt/β-catenin signal 
transduction pathway is much more commonly involved 
in the molecular pathogenesis of HCC than previously 
recognized. Although no clinical studies are available, 
a preclinical study in which β-catenin suppression was 
achieved by antisense modalities has shown that β-catenin 
is essential for the survival and growth of hepatoma 
cells, independently of mutations in the β-catenin gene, 
and therefore this provides a proof of principle for the 
significance of the therapeutic inhibition of β-catenin in 
HCC [122]. 
HEDGEHOG PATHWAY
The Hedgehog (Hh) pathway is essential for 
embryonic development, tissue polarity and cell 
differentiation [123-125]. This pathway is critical in 
the early development of the liver and contributes to 
differentiation between hepatic and pancreatic tissue 
formation [126]. It remains inactive in healthy adult liver 
tissue, except during tissue regeneration and remodeling 
tissue repair, and Hh signaling may also play a role in 
primary liver cancers, such as cholangiocarcinoma and 
HCC [127, 128]. The Hh signaling pathway is complex 
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and requires two cellular receptors, Patched-1 (Ptch-1) 
receptor and Smoothened (Smo), a 7-transmembranous 
domains protein receptor. In the absence of ligand, Ptch-
1 represses Smo, thereby silencing the Hh signaling 
pathway. Binding of the Hh ligands - Sonic Hedgehog 
(Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh) 
- to Ptch-1 liberates Smo from Ptch-1-mediated inhibition, 
thus initiating the propagation of an intracellular 
signaling cascade that leads to the activation and nuclear 
translocation of glioma-associated oncogene homologue 
(Gli) family transcription factors (Gli1, Gli2, Gli3) 
which regulate the expression of Gli-target genes [129]. 
The different Gli proteins show activating or repressing 
transcriptional activators depending on proteolytic 
cleavage of the full-length proteins. Gli1 and Gli2 mainly 
act as transcriptional activators, whereas in the absence or 
inhibition of Hh signaling processing of Gli3 produces a 
repressor form (Gli3R).
Hh has emerged as a critical mediator in the 
development of various diseases, including cancer, when 
aberrantly activated [130]. 
Although the study of Hh signaling in liver cells is in 
its infancy, some studies have shown that activation of the 
Hh pathway is involved in liver carcinogenesis [131-136]. 
Therefore, blockade of the Hh signaling pathway may be 
a potential new therapeutic strategy in HCC. 
The relevance of blocking the Hh pathway for HCC 
treatment can be further supported by the evidence that this 
pathway can cross-talk with the Wnt/β-catenin signaling 
pathway, a well-known oncogenic pathway implicated in 
HCC development [137, 138]. Taken together, these data 
suggest that inhibition of the Hh pathway may provide a 
useful therapeutic option for the treatment of HCC.
INFLAMMATORY PATHWAY (IL-6/STAT3, 
TNF-α, NF-κB, COX-2)
The link between inflammation and cancer was 
first suggested by Rudolph Virchow in 1863, and is now 
a widely-accepted paradigm of carcinogenesis [139, 
140]. Nowadays epidemiological data have undoubtedly 
demonstrated a clear association between chronic 
inflammation and tumor development, including HCC 
[141-143]. Although the molecular mechanisms by which 
chronic inflammation increases the risk of HCC are not 
completely known, compelling evidence gathered over the 
past few years has demonstrated the roles of inflammatory 
factors, such as IL-6, cyclooxygenase 2 (COX-2)/
prostaglandin E2 (PGE2) and tumor necrosis factor α 
(TNF-α) in HCC development [142].
IL-6 mediates its diverse biological effects by 
interacting with a receptor complex consisting of a 
specific ligand-binding protein (IL-6R, gp80) and a 
signal transduction protein (gp130) and regulates the 
JAK/STAT3, Ras/MAP kinase and PI3K/Akt pathways. 
A key feature in our understanding of the regulation of 
IL-6 responses has been the identification of a soluble 
form of the IL-6 receptor (sIL-6R) [144]. When the 
IL-6/sIL-6R complex associates with the membrane-
bound signal-transducing chain, it can induce the signal 
transduction cascade, acting as an agonist and stimulating 
a variety of cellular responses including the proliferation, 
differentiation and activation of inflammatory processes.
A large body of evidence has been accumulating 
in recent years which indicates that IL-6 is involved in 
liver carcinogenesis [143, 145]. In this line, Michael 
Karin’s group showed that IL-6 participates in 
hepatocarcinogenesis, using diethylnitrosamine (DEN)-
induced murine HCC models [146]. They also showed 
that estrogen-mediated inhibition of IL-6 production by 
Kupffer cells reduces liver cancer risk in females and these 
findings not only may be used to prevent HCC in males, 
but also may be a possible clue for the enigma of gender 
difference in HCC occurrence found in epidemiologic 
data [147]. Recently, a retrospective cohort study was 
conducted to examine whether the results observed in 
the mouse models were applicable to human HCC [148]. 
No significant difference in serum IL-6 levels was found 
between female and male chronic hepatitis C patients. 
Unexpectedly, in a multivariate analysis higher serum IL-6 
level was an independent risk factor for HCC development 
in female but not in male chronic hepatitis C patients. 
Therefore, the gender disparity in liver carcinogenesis 
in humans cannot be attributed solely to the difference 
in IL-6 levels. Interestingly, a recent report suggested 
that Foxa factors (Foxa 1 and Foxa2) and their targets 
are central for the sexual dimorphism of HCC [149]. 
The mechanism of gender disparity remains to be further 
investigated.
Nevertheless, many works have reported high serum 
levels of IL-6 in various liver diseases, including HCC. 
Serum IL-6 levels are significantly higher in patients with 
HCC than in healthy individuals [150-152] and higher 
levels of IL-6 have been correlated with tumor mass and 
cancer invasiveness [150, 153]. Moreover, IL-6 is much 
higher in stage III HCC patients than in stage I and II 
patients [151]. As regards sIL-6R, although no significant 
difference in sIL-6R levels were observed between control 
subjects and patients with HCC, sIL-6R levels resulted 
higher in patients with a more advanced stage of disease 
[151, 154]. 
STAT3 is the major mediator of IL-6 and growth 
factor (e.g. EGF, PDGF and HGF) signaling, transmitting 
signals from the cell membrane to the nucleus. STAT3 
activation requires phosphorylation of a critical tyrosine 
residue (Tyr705), which mediates its dimerization, which 
is a prerequisite for nucleus entry and DNA binding. The 
phosphorylation of STAT3 at Tyr705 is most commonly 
mediated by Janus kinases (JAKs), especially JAK2. 
Activated STAT3 can mediate oncogenic transformation 
in cultured cells and promote tumor formation in nude 
mice, thus qualifying STAT3 as a proto-oncogene [155]. 
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STAT3 is constitutively activated in human HCC tissues, 
but not in adjacent non-tumor liver parenchyma or normal 
liver tissue [156, 157]. A recent report demonstrated that 
the STAT3 signaling pathway is very complex and may 
participate in HCC genesis and development by regulating 
the protein expression of other signaling pathways, 
telomerase, apoptosis, the cell cycle and angiogenesis 
[158]. Targeting STAT3 as a potential cancer therapy 
has been extensively investigated [159], and recently 
new small-molecule inhibitors have been developed 
which show to inhibit IL-6-induced STAT3 activation 
and nuclear translocation in HCC cells [160]. Therefore, 
targeting IL-6/STAT3 seems to be a promising strategy for 
HCC therapy.
An inducible enzyme with carcinogenic properties 
that is active within inflamed and malignant tissues is 
cyclooxygenase-2 (COX-2). The COX enzymes (COX-1 
and COX-2) are well-known targets of non-steroidal anti-
inflammatory drugs (NSAIDs). Many epidemiological 
studies have demonstrated that treatment with 
NSAIDs reduces the incidence and mortality of certain 
malignancies, especially gastrointestinal cancer [161]. 
However, conventional NSAIDs non-selectively inhibit 
both the constitutive form COX-1, and the inducible 
form COX-2. Recent evidence indicates that COX-2 is 
an important molecular target for anticancer therapies. 
Its expression is undetectable in most normal tissues, 
and is highly induced by pro-inflammatory cytokines, 
mitogens, tumor promoters and growth factors. It is now 
well-established that COX-2 is chronically overexpressed 
in many premalignant, malignant, and metastatic cancers 
[162], including HCC [163-165]. Overexpression of 
COX-2 in patients with HCC is generally higher in well-
differentiated HCCs compared with less-differentiated 
HCCs or histologically normal liver, suggesting that 
COX-2 may be involved in the early stages of liver 
carcinogenesis [163-165] and increased expression of 
COX-2 in noncancerous liver tissue has been significantly 
associated with postoperative recurrence and shorter 
disease-free survival in patients with HCC [166, 167]. 
In tumors, overexpression of COX-2 leads to an increase 
in prostaglandin levels, which affect many mechanisms 
involved in carcinogenesis, such as angiogenesis, 
inhibition of apoptosis, stimulation of cell growth as well 
as the invasiveness and metastatic potential of tumor cells 
[168]. 
The availability of novel agents that selectively 
inhibit COX-2 (COXIB) has contributed to shed light on 
the role of this molecule. Experimental studies on animal 
models of HCC have shown that NSAIDs, including 
both selective and non-selective COX-2 inhibitors, exert 
chemopreventive as well as therapeutic effects [169-172]. 
However, the key mechanism by which COX-2 inhibitors 
affect HCC cell growth is as yet not fully understood. 
Increasing evidence suggests the involvement of molecular 
targets other than COX-2 in the anti-proliferative effects of 
COX-2 selective inhibitors, including the MAPK cascade 
[173, 174], PI3K/Akt pathway [175] and its upstream 
kinase PDK-1 [176], the anti-apoptotic proteins survivin, 
Bcl-2 and Mcl-1 [177, 178], cyclin-dependent kinase 
inhibitors and cyclins [179], as well as the sacroplasmic/
endoplasmic reticulum calcium ATPase SERCA [180]. 
Interestingly, COX-2-independent effects of celecoxib 
have also been observed during liver carcinogenesis 
in vivo. In the study by Marquez-Rosado [169] neither 
COX-2 expression nor PGE2 production were altered by 
celecoxib treatment, suggesting that celecoxib effects are 
mediated by COX-2/PGE2-independent mechanisms.
Therefore, COX-inhibitors may use both COX-
2-dependent and COX-2-independent mechanisms to 
mediate their antitumor properties [174, 181, 182], 
although their relative contributions toward the in vivo 
effects remain less clear. 
Interestingly, celecoxib also inhibits IL-6/IL-6 
receptor-induced JAK2/STAT3 phosphorylation in human 
HCC cells [183].
The NF-κB pathway has also been recognized 
as an underlying link between inflammation and 
malignancy [184]. The transcription factor NF-κB is a 
ubiquitous transcription factor present in all cell types. In 
unstimulated cells, NF-κB resides in the cytoplasm as a 
heterotrimer consisting of p50, p65, and IκBα. The binding 
of a ligand, such as cytokines or lipopolysaccharide (LPS), 
to a receptor leads to the recruitment and activation of 
an IκB kinase (IKK) complex, which consists of IKKα 
and/or IKKβ catalytic subunits and two molecules of 
NEMO. Phosphorylation of serine residues of IκB 
by IKK leads to IκB ubiquitination and subsequent 
proteosomal degradation. p50 and p65 are then released 
and translocated into the nucleus, where gene expression 
is activated. Most genes linked with tumorigenesis 
are regulated by NF-κB, such as those mediating 
inflammation, cell survival, cell proliferation, invasion, 
angiogenesis, and metastasis.
In recent years, several results have established 
strong support for the critical role of NF-κB in many 
types of cancer, including HCC [185, 186]. NF-κB is 
aberrantly expressed and activated in both human HCC 
tissue and HCC cells [187-189]. Several preclinical 
studies have shown that inhibition of NF-κB signaling 
by pharmacological or genetic approaches [189-192] 
results in an antitumor effect in HCC, suggesting that 
NF-κB is a potential molecular target for HCC therapy. 
Worthy of note is the observation that celecoxib potently 
inhibits the nuclear translocation and activation of NF-
κB by COX-2-dependent and -independent mechanisms 
[169, 181, 193, 194]. Interestingly, we recently reported 
that combination of celecoxib with the novel NF-κB 
inhibitor dehydroxymethyl-epoxyquinomicin (DHMEQ) 
synergistically inhibits cell growth, NF-κB p65 DNA-
binding capacity, and cell proliferation in human HCC 
cells [195], providing a rational basis for the clinical use 
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of this combination in the treatment of liver cancer. 
The important role of inflammatory pathways in liver 
carcinogenesis is further reinforced by recent studies by 
Michael Karin’s team, published in Cell in 2010 [196]. 
Park et al. demonstrated that either dietary or genetic 
obesity is a potent bona fide liver tumor promoter in mice. 
Obesity-promoted HCC development was dependent on 
the production of the tumor-promoting cytokines IL-6 and 
TNF-α, which cause hepatic inflammation and activation 
of the oncogenic transcription factor STAT3. The chronic 
inflammatory response caused by obesity and enhanced 
production of IL-6 and TNF-α ma also increase the risk 
not only of HCC but of other cancers [105, 196].
OTHER POTENTIAL THERAPEUTIC 
TARGETS IN HCC
As stated above, during the multistep biological 
process involved in the development of HCC several 
genetic and epigenetic alterations occur and various 
pathways are involved, including transforming growth 
factor (TGF)-β [197], hepatocyte growth factor (HGF)/
c-MET [198-200], Hyppo [201] and Notch [202, 203] 
signaling. These molecules may represent critical 
therapeutic targets for HCC intervention as well as for 
other cancers.
MOLECULAR-TARGETED THERAPY IN 
HCC
Several recent reviews have been published 
describing in detail the results of clinical trials of 
molecular-targeted agents for the treatment of HCC [204-
208]. Here, we briefly review only some of them, whereas 
an updated list of data accessed up to February 2012 by 
searching the clinicaltrials.gov website on ongoing clinical 
trials in HCC patients is reported (Table 1).
TARGETING THE RAF/MEK/ERK 
PATHWAY
The Raf kinase inhibitor sorafenib (Nexavar, 
BAY43-9006) is currently the most promising molecular 
targeting drug for HCC. Sorafenib, is a multikinase 
inhibitor, which in addition to targeting Raf kinases 
also inhibits VEGFR-2/-3, PDGFR-β, Flt-3 and c-Kit 
[42, 209, 210] (Figure 1). On the basis of the recent 
large randomized phase III study, the Sorafenib HCC 
Assessment Randomized Protocol (SHARP), Sorafenib 
has been approved by the United States (US) Food and 
Drug Administration (FDA) for the treatment of patients 
with advanced HCC [211]. In the SHARP trial median 
overall survival (OS) increased from 7.9 months in the 
placebo group to 10.7 months in the sorafenib group. 
Sorafenib showed a significant benefit also in terms of 
time to progression (TTP), with a median of 5.5 months 
in the sorafenib group and 2.8 months in the placebo 
group. On the basis of these findings, the FDA, European 
Medicine Agency (EMA) and other regulatory authorities 
in the world have approved sorafenib for advanced HCC 
treatment. However, although sorafenib is well tolerated, 
concern for its safety has been expressed. Most common 
adverse events reported in the SHARP trial were diarrhea 
and hand-foot skin reactions [211]. Sorafenib is currently 
undergoing investigation in a phase III study - the 
STORM trial - in HCC patients as an adjuvant therapy 
for the prevention of recurrence following surgery 
or local ablation (http://clinicaltrials.gov/ct2/show/
NCT00692770).
In addition to sorafenib other molecular targeting 
agents have been used in clinical trials for advanced 
HCC treatment (Table 1). However, most of them have 
demonstrated very low responses. The low response 
rate associated with monotherapy indicates the need to 
explore combinations of different molecular targeting 
agents, but also combinations of a single agent with 
conventional cytotoxic drugs. In this context, a phase 
II trial demonstrated that the addition of sorafenib to 
doxorubicin improves progression-free and overall 
survival of patients with advanced HCC [212]. Moreover, 
a phase II trial is currently recruiting patients to determine 
the progression-free survival of sorafenib plus tegafur/
uracil (UFUR) for the treatment of advanced or metastatic 
HCC (NCT00464919).
In addition to Raf inhibition, preclinical studies have 
demonstrated the potential of MEK inhibition to suppress 
hepatoma cell proliferation and tumorigenicity [44, 46, 
213-216]. Huynh et al. recently reported that treatment of 
human HCC xenografts with AZD6244 (ARRY-142886, 
Selumetinib), a selective MEK inhibitor, blocked ERK1/2 
activation, reduced in vivo tumor growth and induced 
apoptosis [44]. Targeting MEK with the selective MEK 
inhibitor PD0325901, a derivative of CI-1040, had in 
vivo chemopreventive effects on HCC development 
in an animal model employing TGF-α-transgenic 
mice with liver cancers induced by diethylnitrosamine 
treatment [217]. In addition, a combination of the MEK 
inhibitor AZD6244 and the conventional cytostatic 
drug doxorubicin enhanced the antineoplastic activity 
of the respective monotherapeutic HCC treatment with 
doxorubicin alone [218]. MEK inhibitors have also been 
shown to potentiate the antitumor activity of selective 
COX-1 and COX-2 inhibitors in suppressing growth and 
inducing apoptosis in human liver cancer cells [174]. 
Taken together, the in vitro and preclinical in vivo 
data show that MEK inhibitors are promising agents for 
HCC treatment. However, a multicenter phase II clinical 
study failed to demonstrate a clinical benefit for AZD6244 
as a single agent in patients with advanced HCC [219]. 
This result suggests that inhibition of MEK signaling 
alone is not sufficient to successfully treat advanced-stage 
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HCC, therefore two clinical trials are currently testing 
AZD6244 in HCC patients with less severe disease, i.e. 
moderate liver dysfunction, and also in association with 
sorafenib (Table 1).
TARGETING THE PI3K/AKT/MTOR 
PATHWAY
The PI3K/Akt/mTOR pathway appears to be 
one of the major contributors to the development and 
maintenance of HCC. Although some preclinical studies 
have demonstrated that PI3K inhibitors such as perifosine, 
LY29004 and wortmannin have anti-HCC activity, no 
studies have been conducted so far at the clinical level.
A phase II Study of MK-2206 (a novel oral potent 
allosteric Akt inhibitor) in advanced HCC patients who 
have not responded or are intolerant to one previous line 
of anti-angiogenic therapy is currently recruiting patients 
(NCT01239355). Of interest, a recent study showed that 
the combination of sorafenib and MK-2206 overcomes 
the resistance of HCC cells to sorafenib at clinically 
achievable concentrations, suggesting the potential use of 
this treatment in HCC patients [220].
Evidence from in vitro experiments, as well as from 
preclinical in vivo data, indicated that mTOR inhibition 
by rapamycin and its analogues everolimus (RAD001) 
significantly reduced the growth of HCC cells and 
improved survival primarily via antiangiogenic effects 
[221-224]. 
A pilot study conducted on 21 patients with advanced 
HCC indicated that sirolimus (rapamycin) was a promising 
drug for the treatment of HCC and a randomized phase 
I/II trial evaluating the rapamycin analog RAD001 
(everolimus) for advanced HCC is currently recruiting 
patients (http://clinicaltrials.gov/ct2/show/NCT00516165). 
Other clinical trials are ongoing to evaluate dose 
limited toxicity and efficacy in advanced HCC patients 
treated with the mTOR inhibitor Torisel (temsirolimus). 
Furthermore, a phase I/II multicentre study to assess the 
safety, tolerability, pharmacokinetics and preliminary 
efficacy of AZD8055, a novel ATP-competitive inhibitor 
of mTOR kinase, is recruiting Asian patients with 
advanced stage HCC (Table 1). 
A topic of considerable current interest concerns 
the signal transduction pathways and molecular 
mechanisms linked to the chemoresistance of tumor 
cells to conventional anticancer drugs. In this context, 
a combination of rapamycin with the conventional 
cytostatic drugs doxorubicin and vinblastine enhances the 
antineoplastic activity of the respective monotherapeutic 
HCC treatment with either doxorubicin or vinblastine 
alone [225, 226]. 
In addition to studies on the combination of mTOR 
inhibitors with conventional chemotherapeutic agents, two 
phase I/II clinical studies are currently recruiting patients 
with advanced HCC to determine the safety/toxicity 
profile of temsirolimus in combination with sorafenib 
(Table 1).
Taken together, the in vitro and preclinical in 
vivo data, as well as the clinical trials, conducted so far 
demonstrate that mTOR inhibitors are promising agents 
for HCC treatment, particularly in combination with 
conventional chemotherapeutic drug therapy.
TARGETING THE VEGF/VEGFR, FGF/
FGFR AND PDGF/PDGFR PATHWAYS
HCC is a hypervascular tumor mainly supplied by 
the hepatic arteries and secretion by HCC cells, tumor-
infiltrating inflammatory cells and hepatic stellate cells of 
factors such as VEGF, bFGF, angiopoietins, PDGF and 
others promotes the sprouting of new vessels from nearby 
existing vessels. 
VEGF, is one of the strongest stimulatory angiogenic 
factors, and is up-regulated in most human tumors, 
including HCC [227, 228]. In a recent systemic review 
and meta-analysis study, the prognostic role of VEGF as 
a predictor of survival in patients with treated HCC was 
established [229]. High tissue VEGF levels predicted poor 
overall (HR=2.15, 95% CI: 1.26-3.68) and disease-free 
(HR=1.69, 95% CI: 1.23-2.33) survival. Similarly, high 
serum VEGF levels predicted poor overall (HR=2.35, 95% 
CI: 1.80-3.07) and disease-free (HR=2.36, 95% CI 1.76-
3.16) survival. Therefore, the inhibition of angiogenesis 
may represent a potential therapeutic target in HCC, 
and many antiangiogenic agents are under evaluation in 
clinical trials in HCC. 
Bevacizumab is a recombinant humanized 
monoclonal antibody against VEGF which has been used 
either as a single agent or in combination with cytotoxic 
or other targeted agents in several clinical studies already 
concluded in patients with advanced HCC [230-236], 
whereas others are still recruiting patients (Table 1). 
Overall, the concluded studies demonstrated that although 
bevacizumab is a well-tolerated agent, the side effects 
associated with its administration, including bleeding, 
hypertension, proteinuria, and thromboembolic events, 
warrant further evaluation.
Other multiple RTK inhibitors that target VEGF are 
under investigation, including brivanib, linifanib (formerly 
ABT-869), vandetanib, and pazopanib.
Recently, in a phase II trial brivanib, a selective dual 
inhibitor of VEGF and FGF signaling, was evaluated as 
a first-line therapy in patients with unresectable, locally 
advanced or metastatic hepatocellular carcinoma. The 
study showed a median OS of 10 months. Brivanib was 
generally well tolerated; the most common adverse effects 
included fatigue, hypertension, and diarrhea [237]. Based 
on these results a randomized, double-blind, multi-center 
phase III study of brivanib versus sorafenib as first-line 
treatment is currently testing the OS of patients with 
advanced HCC who have not received prior systemic 
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therapy (NCT00858871), whereas another phase III trial, 
the BRISK PS Study (Brivanib Study in HCC Patients 
at Risk Post Sorafenib), is evaluating brivanib plus 
best supportive care (BSC) versus placebo plus BSC in 
subjects with advanced HCC who have not responded or 
are intolerant to sorafenib (NCT00825955).
Linifanib (ABT-869) is a novel orally active, potent 
and selective inhibitor of the VEGF and PDGF receptor 
tyrosine kinases. A phase II study on 44 patients with 
advanced HCC showed a response rate of 7%, a median 
PFS of 3.7 months and median survival of 9.3 months 
[238]. This study concluded that linifanib is clinically 
active in advanced HCC, with an acceptable safety profile. 
On the basis of these results, a phase III study of linifanib 
versus sorafenib is ongoing. 
A phase II, placebo-controlled study of vandetanib 
(ZD6474), which targets VEGFR, EGFR and RET 
signaling, showed activity in patients with inoperable HCC 
but failed to meet its primary aim of tumor stabilization 
[239]. However, the PFS and OS results suggest that 
vandetanib has clinical activity in this patient population 
that may warrant further investigation.
Finally, a report from a phase I dose-ranging study of 
pazopanib (GW786034), an oral inhibitor targeting VEGF, 
PDGF and c-kit, showed evidence of antitumor activity 
[240].
TARGETING THE EGFR PATHWAY
Another promising target in HCC is the EGFR 
pathway. As mentioned above, EGFR and its ligand EGF 
play an important role in hepatocarcinogenesis. Two 
therapeutic approaches are currently being employed 
in clinical trials in HCC patients, by using either a 
monoclonal antibody neutralizing the EGFR (cetuximab) 
or three small-molecule tyrosine kinase inhibitors of the 
EGFR (erlotinib, gefinitib and lapatinb). Overall, the 
results have been disappointing. Indeed, in phase II clinical 
trials in which erlotinib, gefitinib, lapatinib and cetuximab 
were assessed in patients with advanced HCC response 
rates (RR) varied in the range of 0%–9%, the median PFS 
time reported was approximately 1.4–3.2 months and OS 
ranged 6.2-13 months [241-244]. Consequently, several 
ongoing clinical trials are combining EGFR inhibitors 
with another therapeutic modality such as cytotoxic drugs 
and other molecular-targeted agents [235, 236, 245, 246] 
(Table 1).
TARGETING THE IGF PATHWAY
Constitutive activation of the IGF-signaling axis 
is frequently observed in HCC [95,96]. In HCC the 
activation of IGF-signaling has antiapoptotic and growth-
promoting effects and acts through multiple signaling 
cascades, including the PI3K/Akt and MAPK pathways. 
As for other pathways, small molecules (such as OSI-
906) and monoclonal antibodies (such as IMC-A12 and 
AVE-1642) targeting IGF signaling are under evaluation 
in clinical trials in HCC patients (Figure 1 and Table 1).
Pre-clinical evidence obtained in vitro in HCC 
cells showed that IMC-A12 decreased cell viability 
and proliferation and blocked ligand-induced IGF-
1R activation. In vivo A12 delayed tumor growth and 
prolonged survival, reducing proliferation rates and 
inducing apoptosis [247]. Therefore, these data suggest 
that IMC-A12 effectively blocks IGF signaling, thus 
providing the rationale for testing this therapy in clinical 
trials. Indeed, an initial phase I study of IMC-A12 
(cituxumumab) yielded a partial response in HCC [248], 
however a subsequent phase II study in patients with 
advanced HCC showed that IMC-A12 is inactive as a 
monotherapy in HCC [249]. 
AVE1642 is a humanized monoclonal antibody that 
specifically blocks IGF-1R signaling. A phase I study 
showed that AVE1642 can be safely combined with 
active doses of sorafenib, and the pharmacokinetics of 
both AVE1642 and sorafenib were not modified at the 
concentrations tested. Interestingly, long-lasting disease 
stabilizations were observed in most patients with 
progressive disease [250].
Recently, OSI-906, a novel orally-efficacious 
small-molecule dual IGF-1R/Insulin receptor (IR) kinase 
inhibitor has been isolated and is being evaluated as a 
therapeutic agent for HCC [251]. OSI-906 is currently 
being tested in a randomized, placebo-controlled, double-
blinded phase 2 study of second-line treatment in patients 
with advanced HCC after failure of first-line treatment 
with sorafenib (NCT01101906; Table 1).
CONCLUSIONS
The recent identification of several key molecular 
pathways implicated in the pathogenesis of HCC has 
led to the development of new targeted therapies for this 
devastating disease. Targeting the various effectors of 
these pathways with pharmacologic inhibitors may inhibit 
HCC cell growth and angiogenesis. Several promising 
novel anticancer agents are currently under investigation 
for the treatment of HCC. Ongoing clinical trials are 
offering hope to improve the progression-free survival of 
patients with advanced HCC. 
The specific action of the new molecular-targeted 
agents minimizes the toxicity typical of systemic 
chemotherapy, although attention needs to be paid to the 
onset and management of side effects related to treatment 
with these new agents. 
Combination therapy with either conventional 
cytotoxic drugs or another inhibitor which targets a 
specific molecule in a different signal transduction 
pathway is also a key approach for improving the 
effectiveness and usefulness of new molecular-targeted 
agents. This avenue of investigation has not been pursued 
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as rigorously as it could be, often due to the conflicting 
interests of the pharmaceutical companies, since different 
companies will often have competing interests for the 
different inhibitors/chemotherapeutic drugs. Nevertheless, 
the field of molecular-targeted therapy in cancer therapy 
has already come a long way. It is not hard to see an even 
brighter future on the horizon. However, many additional 
clinical trials, as well as the development of novel, 
innovative approaches to cure or suppress the further 
development of HCC need to be performed and developed 
to improve therapy in HCC patients.
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